Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAAP phase IIa trial of EMP16-02 for weight loss in overweight and obese adults
2019-004545-32Phase 2Active
- Sponsor
- Empros Pharma
- Start
- Mar 2020
- Modality
- Small Molecules, Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EMP16, orlistat and acarbose in obesity (3 arms), sponsored by Empros Pharma. Started Mar 2020; status: active.
02
Drugs
EMP16orlistatacarbose
03
Conditions
obesity
Beyond the preview
Go deeper on 2019-004545-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004545-32.